Retirement Systems of Alabama Trims Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Retirement Systems of Alabama lessened its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 8.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 129,372 shares of the biotechnology company’s stock after selling 12,481 shares during the quarter. Retirement Systems of Alabama’s holdings in United Therapeutics were worth $46,360,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. ClariVest Asset Management LLC lifted its holdings in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC purchased a new stake in shares of United Therapeutics in the 2nd quarter valued at $30,000. Innealta Capital LLC acquired a new stake in shares of United Therapeutics in the second quarter worth $33,000. USA Financial Formulas purchased a new position in shares of United Therapeutics during the third quarter worth $33,000. Finally, Brooklyn Investment Group acquired a new position in United Therapeutics during the third quarter valued at $33,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Christopher Causey sold 510 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the transaction, the director now directly owns 3,675 shares of the company’s stock, valued at $1,384,115.25. This trade represents a 12.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,485,785.60. This represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 119,340 shares of company stock valued at $44,765,530 over the last ninety days. Insiders own 11.90% of the company’s stock.

United Therapeutics Trading Up 0.0 %

UTHR traded up $0.12 during midday trading on Friday, hitting $361.73. 3,153 shares of the company traded hands, compared to its average volume of 448,382. The company has a market capitalization of $16.15 billion, a price-to-earnings ratio of 15.88, a PEG ratio of 1.05 and a beta of 0.54. The business has a 50 day simple moving average of $369.82 and a two-hundred day simple moving average of $341.06. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same period in the previous year, the firm posted $5.38 EPS. United Therapeutics’s revenue was up 22.9% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analysts Set New Price Targets

UTHR has been the subject of a number of recent research reports. The Goldman Sachs Group lifted their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. HC Wainwright lifted their price target on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Jefferies Financial Group upped their price objective on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. LADENBURG THALM/SH SH lifted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.